Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anxiolytics in development

M Mosconi1, C Chiamulera, G Recchia

  • 1Medical Directorate, Glaxo, Verona, Italy.

International Journal of Clinical Pharmacology Research
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sociodemographic profile, health-related behaviours and experiences of healthcare access in Italian transgender and gender diverse adult population.

Journal of endocrinological investigation·2024
Same author

Apparent autistic traits in transgender people: a prospective study of the impact of gender-affirming hormonal treatment.

Journal of endocrinological investigation·2022
Same author

The interaction between Environmental Enrichment and fluoxetine in inhibiting sucrose-seeking renewal in mice depend on social living condition.

Psychopharmacology·2022
Same author

MPFL reconstruction and tibial tuberosity transposition in patients with patellar instability: May it troubleshots also trochlear dysplasia?

Journal of experimental orthopaedics·2021
Same author

SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people.

Journal of endocrinological investigation·2021
Same author

Brief Environmental Enrichment exposure enhances contextual-induced sucrose-seeking with and without memory reactivation in rats.

Behavioural brain research·2021
Same journal

Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.

International journal of clinical pharmacology research·2006
Same journal

Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial.

International journal of clinical pharmacology research·2006
Same journal

The effect of D-003 (10 mg/day) on biochemical parameters of bone remodelling in postmenopausal women: a randomized, double-blind study.

International journal of clinical pharmacology research·2006
Same journal

Evaluation of cytokine serum levels in patients with plaque-type psoriasis.

International journal of clinical pharmacology research·2006
Same journal

Treatment of guttate psoriasis with a new two-compound product containing calcipotriol and betamethasone dipropionate.

International journal of clinical pharmacology research·2006
Same journal

Etanercept for psoriasis: two case reports.

International journal of clinical pharmacology research·2006
See all related articles

Researchers are developing new anxiety drugs to match benzodiazepine efficacy without side effects. Current research explores diverse mechanisms beyond GABA-A, including CCK-B antagonists and serotonergic agents, suggesting varied pathways for anxiety treatment.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Development

Background:

  • Benzodiazepines (BDZ) are primary anxiety treatments but cause side effects like sedation and abuse.
  • Developing novel anxiolytics with efficacy similar to BDZ but fewer adverse effects is a key research goal.

Purpose of the Study:

  • To review the current status of pharmaceutical research and development for novel anxiolytic drugs.
  • To classify and analyze emerging anxiolytic drug candidates based on their mechanisms of action.

Main Methods:

  • Conducted a "Pharmaprojects" database search for anxiolytic drug candidates.
  • Classified compounds based on their primary biological targets: GABA-A receptor complex, CCK-B antagonists, serotonergic agents, and other mechanisms.

Main Results:

Related Experiment Videos

  • Identified drug candidates targeting the GABA-A receptor complex (15 compounds).
  • Identified drug candidates acting as CCK-B antagonists (5 compounds).
  • Identified drug candidates interacting with serotonergic function (30 compounds), including 5-HT1A agonists, 5-HT2 antagonists, and 5-HT3 antagonists.
  • Identified 22 compounds with other anxiolytic mechanisms.

Conclusions:

  • No single common mechanism underlies the anxiolytic effects of all drugs in development.
  • Different biological pathways appear to be involved in treating distinct anxiety disorders.